SARS-CoV-2 adaptive immunity in nursing home residents following a third dose of the Comirnaty® COVID-19 vaccine.


Por: Giménez E, Albert E, Zulaica J, Torres I, Rusu L, Rodríguez Moreno A, Burgos JS, Peiró S, Salas D, Vanaclocha H, Limón R, Alcaraz MJ, Sánchez-Payá J, Díez-Domingo J, Comas I, Gonzáles-Candelas F, Geller R and Navarro D

Publicada: 24 ago 2022 Ahead of Print: 21 mar 2022
Resumen:
A third Comirnaty® vaccine dose increased SARS-CoV-2-receptor binding domain antibody levels (median of 93-fold) and neutralizing antibody titers against Wuhan-Hu-1 (median, 57-fold), Beta (median, 22-fold), Delta, (median, 43-fold) and Omicron (median, 8-fold) variants, particularly in SARS-CoV-2-naïve individuals, but had a negligible impact on S-reactive T-cell immunity in nursing home residents.

Filiaciones:
Giménez E:
 Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain

Albert E:
 Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain

Zulaica J:
 Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain

Torres I:
 Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain

Rusu L:
 Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain

Rodríguez Moreno A:
 Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain

Burgos JS:
 General Directorate of Research and Healthcare Supervision, Department of Health, Valencia Government, Valencia, Spain

Peiró S:
 Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain

Salas D:
 Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain

 General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain

Vanaclocha H:
 General Directorate of Public Health, Department of Health, Valencia Government, Valencia, Spain

Limón R:
 General Directorate of Healthcare. Department of Health, Valencian Government, Valencia, Spain

Alcaraz MJ:
 Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain

:
 Preventive Medicine Service, Alicante General and University Hospital, Alicante, Spain

 Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain

Díez-Domingo J:
 Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain

Comas I:
 Biomedicine Institute of Valencia, Spanish Research Council (CSIC), Valencia, Spain

 CIBER in Epidemiology and Public Health, Spain

 Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain

Gonzáles-Candelas F:
 Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain

 CIBER in Epidemiology and Public Health, Spain

 Joint Research Unit "Infection and Public Health" FISABIO-University of Valencia, Valencia, Spain

Geller R:
 Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, Valencia, Spain

Navarro D:
 Microbiology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain

 Department of Microbiology, School of Medicine, University of Valencia, Valencia, Spain
ISSN: 10584838





CLINICAL INFECTIOUS DISEASES
Editorial
OXFORD UNIV PRESS INC, JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 75 Número: 1
Páginas: 865-868
WOS Id: 000806001600001
ID de PubMed: 35314856
imagen Green Published

MÉTRICAS